Century Therapeutics, Inc. (IPSC)
USD 1.05
(-10.68%)
USD 1.05
(-10.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -88.56 Million | 14.05 Million | -89 Million | -41.26 Million | -16.16 Million |
| Net Income | -136.67 Million | -130.93 Million | -95.82 Million | -53.57 Million | -244.76 Million |
| Depreciation & Amortization | 13.04 Million | 8.44 Million | 3.74 Million | 1.4 Million | 249 Thousand |
| Deferred income taxes | 2.36 Million | - | - | 4.72 Million | - |
| Stock-based compensation | 14.62 Million | 10.66 Million | 4.66 Million | 876 Thousand | 147 Thousand |
| Change in working capital | 9.16 Million | 123.94 Million | -2.79 Million | 4.86 Million | 2.25 Million |
| Other non-cash items | 8.91 Million | 1.93 Million | 1.2 Million | 444 Thousand | 225.94 Million |
| Investing Cash Flow | 61.13 Million | -13.12 Million | -298.33 Million | -22.75 Million | -19.83 Million |
| Investments in PPE | -13.73 Million | -30.6 Million | -44.97 Million | -9.82 Million | -2.46 Million |
| Acquisitions | -269.81 Million | -238.21 Million | -30.33 Million | -4.72 Million | 24.16 Million |
| Investment purchases | -209.03 Million | -254 Million | -330.03 Million | -49.86 Million | -41.54 Million |
| Sales/Maturities of investments | 283.9 Million | 271.47 Million | 76.66 Million | 41.65 Million | -24.16 Million |
| Other Investing Activities | 269.81 Million | 238.21 Million | 30.33 Million | -4.72 Million | 24.16 Million |
| Financing Cash Flow | -9.72 Million | 27.15 Million | 417.77 Million | 47.69 Million | 74.83 Million |
| Debt repayment | -10.24 Million | - | - | -9.73 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 516 Thousand | 27.15 Million | 221.61 Million | 38.1 Million | 74.83 Million |
| Other Financing Activities | -10.24 Million | 27.15 Million | 196.15 Million | 9.59 Million | 74.83 Million |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | -2.36 Million | -4.78 Million | -1.84 Million | 2.06 Million | 1.23 Million |
| Inventory | - | - | - | - | - |
| Other working capital | 11.52 Million | 128.73 Million | -949 Thousand | 2.8 Million | 1.02 Million |
| Cash at beginning of period | 84.26 Million | 58.16 Million | 27.72 Million | 44.06 Million | 31.42 Million |
| Cash at end of period | 47.32 Million | 86.24 Million | 58.16 Million | 27.72 Million | 70.26 Million |
| Capital Expenditure | -13.73 Million | -30.6 Million | -44.97 Million | -9.82 Million | -2.46 Million |
| Effect of forex changes on cash | 220 Thousand | - | - | - | - |
| Net cash flow / Change in cash | -36.94 Million | 28.08 Million | 30.43 Million | -16.33 Million | 38.83 Million |
| Free Cash Flow | -102.3 Million | -16.55 Million | -133.97 Million | -51.09 Million | -18.62 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -31.22 Million | -31.2 Million | -28.06 Million | -39.39 Million | -136.67 Million | -32.72 Million |
| Depreciation & Amortization | 3.29 Million | 3.46 Million | 3.22 Million | 3.55 Million | 13.04 Million | 3.35 Million |
| Deferred income taxes | - | - | - | -13.55 Million | 2.36 Million | - |
| Stock-based compensation | 3.31 Million | 3.5 Million | 3.2 Million | 3.56 Million | 14.62 Million | 3.97 Million |
| Change in working capital | 8.33 Million | 713 Thousand | -9.04 Million | -2.91 Million | 9.16 Million | 12.18 Million |
| Other non-cash items | -12.05 Million | 8.5 Million | 9.39 Million | 22.51 Million | 8.91 Million | -437 Thousand |
| Investing Cash Flow | 39.19 Million | -33.86 Million | 11.54 Million | 18.6 Million | 61.13 Million | 4.21 Million |
| Investments in PPE | 804 Thousand | -265 Thousand | -539 Thousand | -980 Thousand | -13.73 Million | -3.26 Million |
| Acquisitions | - | -9.6 Million | - | 92.14 Million | -269.81 Million | -7.48 Million |
| Investment purchases | 88.94 Million | -53.86 Million | -35.08 Million | -9.69 Million | -209.03 Million | -57.49 Million |
| Sales/Maturities of investments | -179.18 Million | 29.86 Million | 47.16 Million | 29.27 Million | 283.9 Million | 64.98 Million |
| Other Investing Activities | 128.62 Million | -23.99 Million | 12.08 Million | 19.58 Million | 269.81 Million | 7.48 Million |
| Financing Cash Flow | 273 Thousand | 56.69 Million | 18.19 Million | -356 Thousand | -9.72 Million | 300 Thousand |
| Debt repayment | - | - | - | -10.24 Million | -10.24 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -356 Thousand | - | - |
| Common Stock Issuance | -56.32 Million | 56.69 Million | 366 Thousand | -356 Thousand | 516 Thousand | 300 Thousand |
| Other Financing Activities | 56.59 Million | 56.69 Million | 17.82 Million | 10.24 Million | -10.24 Million | 300 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -757 Thousand | -1.87 Million | 689 Thousand | -2.88 Million | -2.36 Million | 3.99 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 7.14 Million | 2.59 Million | -9.73 Million | -24 Thousand | 11.52 Million | 8.18 Million |
| Cash at beginning of period | 41.45 Million | 46.81 Million | 47.32 Million | 55.3 Million | 84.26 Million | 66.41 Million |
| Cash at end of period | 55.43 Million | 41.45 Million | 46.81 Million | 47.32 Million | 47.32 Million | 57.28 Million |
| Capital Expenditure | 804 Thousand | -265 Thousand | -539 Thousand | -980 Thousand | -13.73 Million | -3.26 Million |
| Effect of forex changes on cash | - | - | - | - | 220 Thousand | - |
| Net cash flow / Change in cash | 13.97 Million | -5.35 Million | -512 Thousand | -7.98 Million | -36.94 Million | -9.13 Million |
| Free Cash Flow | -27.52 Million | -27.59 Million | -30.78 Million | -27.21 Million | -102.3 Million | -16.91 Million |
DXC
AJAX
HYFXF
TPII
AIRS
GGAL